Cargando…

Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence

Venous thromboembolic disease (VTED) is a common and clinically important complication in patients with cancer, contributing to its mortality and morbidity. Direct oral anticoagulant agents (DOACs), including direct thrombin inhibitors and direct factor Xa inhibitors, are as effective as vitamin K a...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Escobar, I., Brozos-Vázquez, E., Gutierrez Abad, D., Martínez-Marín, V., Pachón, V., Muñoz Martín, A. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084841/
https://www.ncbi.nlm.nih.gov/pubmed/33206333
http://dx.doi.org/10.1007/s12094-020-02506-4
_version_ 1783686237422354432
author García-Escobar, I.
Brozos-Vázquez, E.
Gutierrez Abad, D.
Martínez-Marín, V.
Pachón, V.
Muñoz Martín, A. J.
author_facet García-Escobar, I.
Brozos-Vázquez, E.
Gutierrez Abad, D.
Martínez-Marín, V.
Pachón, V.
Muñoz Martín, A. J.
author_sort García-Escobar, I.
collection PubMed
description Venous thromboembolic disease (VTED) is a common and clinically important complication in patients with cancer, contributing to its mortality and morbidity. Direct oral anticoagulant agents (DOACs), including direct thrombin inhibitors and direct factor Xa inhibitors, are as effective as vitamin K antagonists for the treatment of VTED and are associated with less frequent and severe bleeding. They have advantages over low-molecular-weight heparin, but comparative long-term efficacy and safety data are lacking for these compounds. Recent randomized clinical trials suggest a role for DOACs in the treatment of VTED in patients with cancer. This review will discuss the existing evidence and future perspectives on the role of DOACs in the treatment of VTE based on the current evidence about their overall efficacy and safety and the limited information in patients with cancer; in addition, we will briefly review their pharmacokinetic properties with special reference to potential interactions.
format Online
Article
Text
id pubmed-8084841
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-80848412021-05-05 Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence García-Escobar, I. Brozos-Vázquez, E. Gutierrez Abad, D. Martínez-Marín, V. Pachón, V. Muñoz Martín, A. J. Clin Transl Oncol Review Article Venous thromboembolic disease (VTED) is a common and clinically important complication in patients with cancer, contributing to its mortality and morbidity. Direct oral anticoagulant agents (DOACs), including direct thrombin inhibitors and direct factor Xa inhibitors, are as effective as vitamin K antagonists for the treatment of VTED and are associated with less frequent and severe bleeding. They have advantages over low-molecular-weight heparin, but comparative long-term efficacy and safety data are lacking for these compounds. Recent randomized clinical trials suggest a role for DOACs in the treatment of VTED in patients with cancer. This review will discuss the existing evidence and future perspectives on the role of DOACs in the treatment of VTE based on the current evidence about their overall efficacy and safety and the limited information in patients with cancer; in addition, we will briefly review their pharmacokinetic properties with special reference to potential interactions. Springer International Publishing 2020-11-18 2021 /pmc/articles/PMC8084841/ /pubmed/33206333 http://dx.doi.org/10.1007/s12094-020-02506-4 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
García-Escobar, I.
Brozos-Vázquez, E.
Gutierrez Abad, D.
Martínez-Marín, V.
Pachón, V.
Muñoz Martín, A. J.
Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence
title Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence
title_full Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence
title_fullStr Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence
title_full_unstemmed Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence
title_short Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence
title_sort direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084841/
https://www.ncbi.nlm.nih.gov/pubmed/33206333
http://dx.doi.org/10.1007/s12094-020-02506-4
work_keys_str_mv AT garciaescobari directoralanticoagulantsforthetreatmentandpreventionofvenousthromboembolisminpatientswithcancercurrentevidence
AT brozosvazqueze directoralanticoagulantsforthetreatmentandpreventionofvenousthromboembolisminpatientswithcancercurrentevidence
AT gutierrezabadd directoralanticoagulantsforthetreatmentandpreventionofvenousthromboembolisminpatientswithcancercurrentevidence
AT martinezmarinv directoralanticoagulantsforthetreatmentandpreventionofvenousthromboembolisminpatientswithcancercurrentevidence
AT pachonv directoralanticoagulantsforthetreatmentandpreventionofvenousthromboembolisminpatientswithcancercurrentevidence
AT munozmartinaj directoralanticoagulantsforthetreatmentandpreventionofvenousthromboembolisminpatientswithcancercurrentevidence
AT directoralanticoagulantsforthetreatmentandpreventionofvenousthromboembolisminpatientswithcancercurrentevidence